Trial Profile
Expanding the Pool in Orthotopic Heart Transplantation: The Use of Hepatitis C Positive Donor Hearts in Hepatitis C Negative Recipients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2024 Planned End Date changed from 1 Dec 2023 to 31 Dec 2024.
- 03 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 31 Dec 2024.
- 06 Sep 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.